BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2025-11
180 industry Phase 2/3 trial readout(s) and 37 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2025-11 est. | P3 | Winston Laboratories | NCT01341548 Civamide Nasal Solution for Cluster Headache | Episodic Cluster Headache | unknown | 180 |
| 2025-11 est. | P3 | Korea Otsuka Pharmaceutical Co., Ltd. | NCT03423680 A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression | Depression, Bipolar | unknown | 390 |
| 2025-11 est. | P2 | Heron Therapeutics HRTX | NCT03922048 Pediatric Postoperative Analgesia Herniorrhaphy Study | Analgesia | withdrawn | |
| 2025-11 est. | P1/P2 | Treadwell Therapeutics, Inc | NCT04521413 Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Advanced Solid Malignancies | unknown | 170 |
| 2025-11 est. | P1/P2 | Deciphera Pharmaceuticals, LLC | NCT05080621 Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) | Gastrointestinal Stromal Tumors | withdrawn | |
| 2025-11 est. | P1/P2 | Perceive Biotherapeutics, Inc. | NCT05380492 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration | Age-related Macular Degeneration; Geographic Atrophy | unknown | 45 |
| 2025-11 est. | P2/P3 | Shanghai JMT-Bio Inc. | NCT05427383 KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy | Stomach Cancer | recruiting | 286 |
| 2025-11 est. | P1/P2 | Intima Bioscience, Inc. | NCT05566223 CISH Inactivated TILs in the Treatment of NSCLC | Carcinoma, Non-Small-Cell Lung; Metastatic Non Small Cell Lung Cancer; Stage IV Non-small Cell Lung | withdrawn | |
| 2025-11 est. | P1/P2 | Beijing Mabworks Biotech Co., Ltd. | NCT05806099 A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL | Non-Hodgkin's Lymphoma | recruiting | 132 |
| 2025-11 est. | P1/P2 | Biocad | NCT06120582 Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN) | Hemophilia B | recruiting | 28 |
| 2025-11 est. | P2 | Beacon Therapeutics BBT | NCT06275620 A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN) | X-Linked Retinitis Pigmentosa | enrolling by invitation | 24 |
| 2025-11 est. | P1/P2 | Lantheus Medical Imaging LNTH | NCT06298916 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer | Metastatic Sarcoma; Esophageal Cancer; Gastric Cancer; Pancreatic Cancer; Colorectal Cancer; Sarcoma | recruiting | 26 |
| 2025-11 est. | P1/P2 | ENCell | NCT06328725 Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | unknown | 88 |
| 2025-11 est. | P3 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT06449027 Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects. | Breast Cancer Subjects | active not recruiting | 211 |
| 2025-11 est. | P3 | TBF Genie Tissulaire | NCT06450470 Use of a Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus | Progressive Keratoconus | recruiting | 116 |
| 2025-11 est. | P2 | Laboratorio Elea Phoenix S.A. | NCT06629389 Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms | Parkinson Disease | recruiting | 88 |
| 2025-11 est. | P1/P2 | Helios Cardio Inc. | NCT06730828 Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects | Atrial Fibrillation, Postoperative | recruiting | 80 |
| 2025-11 est. | P2 | Aer Therapeutics | NCT06731959 A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD | COPD | not yet recruiting | 100 |
| 2025-11 est. | P1/P2 | Rion Inc. | NCT06793748 Study to Evaluate the Safety, Tolerability, and Efficacy of PEP-TISSEEL in Subjects With Chronic Radiation Ulcer | Chronic Radiation Ulcer | not yet recruiting | 184 |
| 2025-11 est. | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT06875934 A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis | Moderate to Severe Plaque Psoriasis | active not recruiting | 145 |
| 2025-11-01 est. | P1/P2 | CERM INC. | NCT06869252 Autologous Adipose Cells Therapy | Hair Loss/Baldness; Wrinkle Appearance; Volume; Fine Lines; Skin Elasticity; Hair Thinning; Skin Pig | recruiting | 40 |
| 2025-11-01 est. | P2 | ORA, Inc. | NCT07068958 A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye | Dry Eye Disease (DED) | not yet recruiting | 200 |
| 2025-11-02 | P3 | Adlai Nortye Biopharma Co., Ltd. ANL | NCT04338399 The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC | Head and Neck Cancer | completed | 487 |
| 2025-11-02 | P3 | Immunovant Sciences GmbH IMVT | NCT05517421 Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease | Thyroid Eye Disease | completed | 114 |
| 2025-11-03 | P2 | Astellas Pharma Europe Ltd. | NCT01294020 Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf® | Intestine Transplantation; Kidney Transplantation; Lung Transplantation; Liver Transplantation; Hear | completed | 81 |
| 2025-11-03 | P2 | Eisai Co., Ltd. | NCT04238715 A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion | Cholangiocarcinoma | completed | 63 |
| 2025-11-03 | P1/P2 | Visara, Inc. | NCT05456828 A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration | Neovascular Age-related Macular Degeneration | completed | 56 |
| 2025-11-03 | P3 | GlaxoSmithKline | NCT05630820 Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) | Chronic Hepatitis B; Hepatitis B, Chronic | completed | 857 |
| 2025-11-03 | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06542614 Treatment of Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | completed | 209 |
| 2025-11-03 | P3 | RDC Clinical Pty Ltd | NCT06837961 LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases | Healthy Volunteer; Immune Response | completed | 241 |
| 2025-11-03 | P2 | IVIEW Therapeutics Inc. | NCT07161011 Phase 2b Controlled Study of Dosing Techniques - Part B | Dry Eye | completed | 15 |
| 2025-11-04 | P3 | AstraZeneca AZN | NCT04008706 Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients | Chronic Lymphocytic Leukemia | completed | 552 |
| 2025-11-04 | P3 | Novartis Pharmaceuticals NVS | NCT04788615 Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS | Multiple Sclerosis | completed | 185 |
| 2025-11-04 | P3 | ModernaTX, Inc. | NCT05085366 A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | Cytomegalovirus Infection | terminated | 7454 |
| 2025-11-04 | P2 | Glycomine, Inc. | NCT05549219 24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG | Pmm2-CDG; Phosphomannomutase 2 Deficiency | completed | 27 |
| 2025-11-04 | P3 | A. Vogel AG | NCT06795776 Eschscholzia Study | Sleep | completed | 104 |
| 2025-11-04 | P3 | Colgate Palmolive CL | NCT07257042 Oothpaste Containing 8% Arginine Compared to Colgate Cavity Protection Toothpaste in Reducing Dentinal Hypersensitivity | Hypersensitivity | completed | 80 |
| 2025-11-05 | P2 | Merck Sharp & Dohme LLC MRK | NCT02625961 Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475- | Bladder Cancer | terminated | 296 |
| 2025-11-05 | P3 | Neurocrine Biosciences NBIX | NCT04400331 Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease | Chorea, Huntington | terminated | 154 |
| 2025-11-05 | P1/P2 | Genmab GMAB | NCT05721222 Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) | Renal Cell Carcinoma; Nasopharyngeal Carcinoma; Non Hodgkin Lymphoma | terminated | 42 |
| 2025-11-05 | P2 | Noah Pharmaceuticals, Inc. NOAH | NCT06597058 Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill | Alzheimer Disease | completed | 121 |
| 2025-11-05 | P3 | Haisco Pharmaceutical Group Co., Ltd. | NCT06799546 A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor The | PNH | completed | 73 |
| 2025-11-06 | P2 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT05593029 A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder | Major Depressive Disorder | completed | 929 |
| 2025-11-06 | P2/P3 | Abcuro, Inc. | NCT05721573 A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis | Inclusion Body Myositis | completed | 272 |
| 2025-11-06 | P3 | DBV Technologies DBVT | NCT05741476 Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age | Allergy, Peanut | active not recruiting | 600 |
| 2025-11-06 | P2 | Regor Pharmaceuticals Inc. | NCT06867718 Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions | Obesity or Overweight | completed | 267 |
| 2025-11-07 | P1/P2 | Ocellaris Pharma, Inc. | NCT04260802 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Cancer; Neoplasms; Metastatic Cancer; Triple Negative Breast Cancer; Gastric Cancer; Cervical Cancer | terminated | 73 |
| 2025-11-07 | P3 | Scynexis, Inc. SCYX | NCT05178862 A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluc | Candidiasis, Invasive; Candidemia | terminated | 68 |
| 2025-11-07 | P3 | Pfizer PFE | NCT05348915 A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease | Sickle Cell Disease; Vaso-occlusive Crisis; Vaso-occlusive Pain Episode in Sickle Cell Disease | terminated | 242 |
| 2025-11-07 | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06194201 A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis | Patients With Candidemia and/or Invasive Candidiasis | completed | 61 |
| 2025-11-07 | P2 | Biohaven Therapeutics Ltd. BHVN | NCT06419608 Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression | Major Depressive Disorder | completed | 336 |
| 2025-11-07 est. | P2 | Reinhold Vieth | NCT07109609 Topical Menthol For Tear Secretion | Healthy; Dry Eyes | enrolling by invitation | 30 |
| 2025-11-09 est. | P1/P2 | Shanghai Jiatan Pharmatech Co., Ltd | NCT06117566 A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors | Solid Tumor | recruiting | 100 |
| 2025-11-09 | P1/P2 | Unither Pharmaceuticals, France | NCT07075224 Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution | Mydriasis | completed | 20 |
| 2025-11-10 | P2 | Leidos Life Sciences LDOS | NCT05077332 LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) | 2019 Novel Coronavirus Disease; 2019 Novel Coronavirus Infection; 2019-nCoV Disease; 2019-nCoV Infec | completed | 4 |
| 2025-11-10 | P3 | AbbVie ABBV | NCT06399718 A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants | Masseter Muscle Prominence | completed | 207 |
| 2025-11-10 | P3 | Mannkind Corporation MNKD | NCT06418711 ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension | MAC Lung Disease; Treatment Refractory MAC Lung Disease; Mycobacterium Infections, Nontuberculous | terminated | 132 |
| 2025-11-10 est. | P1/P2 | Sinocelltech Ltd. | NCT06801509 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine | Herpes Zoster | not yet recruiting | 540 |
| 2025-11-10 | P2 | Eli Lilly and Company LLY | NCT06859294 A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis | Rheumatoid Arthritis | terminated | 35 |
| 2025-11-10 | P3 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07704697 Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan | Essential Hypertension | completed | 346 |
| 2025-11-11 | P3 | GlaxoSmithKline | NCT05630807 Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) | Chronic Hepatitis B; Hepatitis B, Chronic | completed | 981 |
| 2025-11-11 | P2 | Cyrano Therapeutics, Inc. | NCT06019000 Study of CYR-064 Versus Placebo in Patients. | Hyposmia | completed | 151 |
| 2025-11-11 | P3 | Boryung Pharmaceutical Co., Ltd | NCT06165250 A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C | Essential Hypertension; Primary Hypercholesterolemia | completed | 151 |
| 2025-11-11 | P2 | Alkermes, Inc. ALKS | NCT06555783 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 | Narcolepsy Type 2 | completed | 93 |
| 2025-11-12 | P3 | Eli Lilly and Company LLY | NCT04396236 A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | Migraine | terminated | 847 |
| 2025-11-12 | P2 | Bristol-Myers Squibb BMY | NCT05136677 A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Pa | Mesothelioma, Malignant | completed | 102 |
| 2025-11-12 | P2 | Neurocrine Biosciences NBIX | NCT05226780 Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE | SCN8A Developmental and Epileptic Encephalopathy Syndrome | terminated | 8 |
| 2025-11-12 | P2 | Curacle Co., Ltd. | NCT05718375 Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria | Diabetic Nephropathies | completed | 240 |
| 2025-11-12 | P2/P3 | Praxis Precision Medicines PRAX | NCT05818553 A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE) | SCN2A Encephalopathy; SCN8A Encephalopathy | active not recruiting | 77 |
| 2025-11-12 est. | P1/P2 | GI Innovation, Inc. | NCT05824975 A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Tra | Advanced Solid Tumor; Metastatic Solid Tumor; Soft Tissue Sarcoma (STS); Platinum-resistant Ovarian | recruiting | 358 |
| 2025-11-12 | P3 | Ascletis Pharmaceuticals Co., Ltd. | NCT06248008 A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris | Acne | completed | 240 |
| 2025-11-12 | P2 | AbbVie ABBV | NCT06605599 Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder | Bipolar I Disorder; Bipolar II Disorder | completed | 161 |
| 2025-11-13 | P2/P3 | Vertex Pharmaceuticals Incorporated VERX | NCT03655678 A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia | Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn; Hematologic Diseases; Hemoglobinopathies | completed | 59 |
| 2025-11-13 est. | P1/P2 | Inventage Lab., Inc. | NCT05345509 A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003. | Alzheimer Disease | active not recruiting | 62 |
| 2025-11-13 | P2 | ModernaTX, Inc. | NCT05606965 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults | Influenza | completed | 172 |
| 2025-11-13 | P3 | Zenas BioPharma (USA), LLC ZBIO | NCT05662241 A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease | IgG4 Related Disease | active not recruiting | 194 |
| 2025-11-13 | P3 | COMPASS Pathways CMPS | NCT05711940 Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD | Treatment Resistant Depression | active not recruiting | 572 |
| 2025-11-13 | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05745363 Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer | Differentiated Thyroid Cancer | completed | 33 |
| 2025-11-13 | P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06236295 Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term | Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis | completed | 303 |
| 2025-11-13 | P3 | Shandong Suncadia Medicine Co., Ltd. | NCT06672172 A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise | Type 2 Diabetes | completed | 284 |
| 2025-11-14 | P3 | Eli Lilly and Company LLY | NCT03432286 A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine | Episodic Migraine | active not recruiting | 533 |
| 2025-11-14 | P3 | Sanofi SNY | NCT04458051 Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) | Primary Progressive Multiple Sclerosis | completed | 767 |
| 2025-11-14 | P2 | CinDome Pharma, Inc. | NCT05832151 A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis | Diabetic Gastroparesis | completed | 382 |
| 2025-11-14 | P3 | Eli Lilly and Company LLY | NCT05931367 A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee | Obesity; Overweight; Osteo Arthritis Knee | completed | 445 |
| 2025-11-14 | P1/P2 | Auregen Biotherapeutics, SA | NCT06072040 Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia | Microtia | terminated | 3 |
| 2025-11-14 | P1/P2 | Auregen Biotherapeutics, SA | NCT06078566 Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 | Microtia | terminated | 1 |
| 2025-11-14 | P1/P2 | Clarametyx Biosciences, Inc. | NCT06159725 A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis | Persistent Infection; Cystic Fibrosis | completed | 43 |
| 2025-11-14 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT06284915 Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers | Meningococcal Immunisation; Healthy Volunteers | completed | 840 |
| 2025-11-14 | P2 | Ascendis Pharma Growth Disorders A/S ASND | NCT06433557 A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia | Achondroplasia | active not recruiting | 22 |
| 2025-11-14 | P2 | Alcon Research ALC | NCT06441643 Next Generation Rocklatan | Open Angle Glaucoma; Ocular Hypertension | completed | 646 |
| 2025-11-14 | P2 | Enterprise Therapeutics Ltd EPD | NCT06478706 A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis | Cystic Fibrosis | completed | 57 |
| 2025-11-15 | P1/P2 | Lokon Pharma AB | NCT02705196 LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | Pancreatic Cancer | completed | 51 |
| 2025-11-15 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT05794230 Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Ind | Meningococcal Immunisation; Healthy Volunteers | completed | 1528 |
| 2025-11-16 | P2 | medac GmbH | NCT03156790 PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia | Acute B-Cell Lymphoblastic Leukaemia | terminated | 40 |
| 2025-11-16 est. | P3 | Celgene | NCT06232707 A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Multiple Myeloma | withdrawn | |
| 2025-11-16 est. | P2/P3 | Novavax NVAX | NCT06482359 Lot Consistency Study of COVID-19 and Influenza Combination Vaccine | COVID-19; Influenza | withdrawn | |
| 2025-11-17 est. | P3 | Novartis Pharmaceuticals NVS | NCT03081234 Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer | Breast Cancer | withdrawn | |
| 2025-11-17 | P2 | Veralox Therapeutics | NCT05785819 A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia | Thrombocytopenia, Immune; Heparin Induced Thrombocytopenia | terminated | 24 |
| 2025-11-17 | P2 | Trishula Therapeutics, Inc. | NCT06119217 Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients | Pancreatic Cancer | completed | 194 |
| 2025-11-17 | P2 | Sarfez Pharmaceuticals, Inc. | NCT06206512 Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder | Heart Failure; Overactive Bladder; Incontinence | completed | 24 |
| 2025-11-17 | P3 | ModernaTX, Inc. | NCT06694389 Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age | COVID-19; Influenza | completed | 2457 |
| 2025-11-17 | P2 | Evommune, Inc. EVMN | NCT06723405 Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis | Atopic Dermatitis (AD); Eczema; Eczema Atopic Dermatitis | completed | 71 |
| 2025-11-17 | P3 | Janssen Research & Development, LLC | NCT06934226 A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | active not recruiting | 752 |
| 2025-11-18 | P3 | F2G Ltd | NCT05101187 Olorofim Aspergillus Infection Study | Invasive Aspergillosis | completed | 225 |
| 2025-11-18 | P3 | Vifor Fresenius Medical Care Renal Pharma | NCT05136664 Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects | Hyperkalemia; Renal Insufficiency, Chronic | completed | 262 |
| 2025-11-18 | P2 | AudioCure Pharma GmbH | NCT05776459 Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL) | Hearing Loss, Sensorineural | completed | 223 |
| 2025-11-18 | P2 | NovoCure Ltd. NVCR | NCT06390059 EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Du | Metastatic Pancreatic Ductal Adenocarcinoma | completed | 84 |
| 2025-11-18 | P3 | Eli Lilly and Company LLY | NCT06588296 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight | Psoriatic Arthritis; Obesity | completed | 279 |
| 2025-11-18 | P2 | Organ, Tissue, Regeneration, Repair and Replacement | NCT06700824 A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke | Endovascular Thrombectomy; Ischemic Cerebrovascular Accident | completed | 60 |
| 2025-11-18 | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06816251 A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy | Non-obstructive Hypertrophic Cardiomyopathy | completed | 84 |
| 2025-11-18 | P2 | TriGemX Bio, Inc. | NCT07116499 A Study of K-645 in the Treatment of Multiple Migraine Attacks | Migraine | terminated | 134 |
| 2025-11-19 | P3 | Amgen AMGN | NCT03836040 Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine | Migraine | active not recruiting | 457 |
| 2025-11-19 | P2 | AbbVie ABBV | NCT05291234 A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-9 | Alzheimer's Disease (AD) | completed | 106 |
| 2025-11-19 | P3 | CSL Behring | NCT05819775 CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema | Hereditary Angioedema (HAE) | completed | 22 |
| 2025-11-19 | P3 | Novo Nordisk A/S NVO | NCT06065540 A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes T | Type 2 Diabetes Mellitus | completed | 2734 |
| 2025-11-20 | P1/P2 | Akeso | NCT05214482 A Study of AK112 in Advanced Malignant Tumors | Advanced Malignant Tumors | completed | 154 |
| 2025-11-20 | P3 | Hoffmann-La Roche | NCT05271409 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibo | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) | active not recruiting | 139 |
| 2025-11-20 | P3 | Amgen AMGN | NCT05565560 A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | completed | 21 |
| 2025-11-20 | P2 | Melinta Therapeutics, LLC | NCT05599295 Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections | Acute Bacterial Skin and Skin Structure Infection | completed | 118 |
| 2025-11-20 | P1/P2 | InxMed (Shanghai) Co., Ltd. | NCT06030258 IN10018 Combination Therapy in Treatment-naïve ES-SCLC | Small Cell Lung Cancer Extensive Stage | active not recruiting | 120 |
| 2025-11-20 | P3 | AbbVie ABBV | NCT06068855 A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants | Masseter Muscle Prominence | completed | 249 |
| 2025-11-20 | P2 | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | NCT06309355 Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis | Atopic Dermatitis | completed | 35 |
| 2025-11-20 | P1/P2 | Genmab GMAB | NCT06391775 Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy | Malignant Solid Tumor | terminated | 21 |
| 2025-11-20 | P2 | Jemincare | NCT06438757 Trial of JYB1904 in Patients With Allergic Asthma | Allergic Asthma | completed | 69 |
| 2025-11-20 | P3 | Cutia Therapeutics(Wuxi)Co.,Ltd | NCT06585696 A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101) | Glabellar Frown Lines | completed | 554 |
| 2025-11-20 | P2 | Merck Sharp & Dohme LLC MRK | NCT06664801 A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) | Pulmonary Arterial Hypertension | completed | 164 |
| 2025-11-20 | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06851442 Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positi | Breast Cancer | terminated | 8 |
| 2025-11-20 est. | P2 | Beijing Tide Pharmaceutical Co., Ltd | NCT07121101 To Evaluate the Safety, Efficacy and Kinetic Characteristics of TRD205 Tablets for Postoperative Analgesia After Unilateral Hip Arthroplasty | Postoperative Analgesia After Unilateral Hip Arthroplasty | not yet recruiting | 40 |
| 2025-11-21 | P3 | Insmed Incorporated INSM | NCT04677569 Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium | Mycobacterium Infections, Nontuberculous | completed | 425 |
| 2025-11-21 | P3 | CSL Behring | NCT04739059 Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks | Hereditary Angioedema | completed | 171 |
| 2025-11-21 | P1/P2 | Blueprint Medicines Corporation | NCT04773782 A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | Solid Tumor, Unspecified, Child; Relapsed Solid Neoplasm; CNS Tumor | completed | 29 |
| 2025-11-21 | P1/P2 | Amgen AMGN | NCT05322577 A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junc | Gastric Cancer; Gastroesophageal Junction Cancer | terminated | 72 |
| 2025-11-21 | P2 | Novo Nordisk A/S NVO | NCT06409130 Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease | Alcohol-related Liver Disease | completed | 270 |
| 2025-11-21 | P2 | AstraZeneca AZN | NCT06579092 Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity | Obesity or Overweight | completed | 310 |
| 2025-11-21 | P3 | Eli Lilly and Company LLY | NCT06584916 A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MA | Obesity; Overweight | completed | 376 |
| 2025-11-21 | P2 | Palvella Therapeutics, Inc. PVLA | NCT06653842 A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformatio | Cutaneous Venous Malformations | active not recruiting | 15 |
| 2025-11-21 | P2 | Korea Arlico Pharm. Co., Ltd | NCT07061925 To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis | Acute Bronchitis | completed | 169 |
| 2025-11-21 | P2 | The United Bio-Technology (Hengqin) Co., Ltd. | NCT07163624 UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study | Type 2 Diabetes Mellitus (T2DM) | completed | 211 |
| 2025-11-22 | P1/P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT06713499 A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis | Children and Adolescents With Moderate-to-severe Atopic Dermatitis | completed | 51 |
| 2025-11-22 | P2 | Portal Therapeutics, Inc. | NCT06971900 GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria | Erythropoietic Protoporphyria (EPP) | completed | 28 |
| 2025-11-24 | P3 | AstraZeneca AZN | NCT05110261 Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China | Lower Respiratory Tract Infection | completed | 800 |
| 2025-11-24 | P2 | Kite, A Gilead Company | NCT05459571 Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma | Relapsed or Refractory Large B-cell Lymphoma | completed | 35 |
| 2025-11-24 | P3 | AstraZeneca AZN | NCT06344104 A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants Wi | Uncontrolled Hypertension; Resistant Hypertension | completed | 326 |
| 2025-11-24 | P3 | Colgate Palmolive CL | NCT07276672 Efficacy of a Toothpaste Containing Hydrogen Peroxide as Compared to a Regular Fluoride Toothpaste Without Hydrogen Peroxide in the Immediate Removal of Tooth S | Whitening | completed | 80 |
| 2025-11-25 | P2 | RHEACELL GmbH & Co. KG | NCT04971161 Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb) | Skin Ulcer Venous Stasis Chronic | completed | 159 |
| 2025-11-25 | P2/P3 | Hutchmed HCM | NCT05535933 HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Warm Antibody Autoimmune Hemolytic Anemia | active not recruiting | 111 |
| 2025-11-25 | P2 | Altimmune, Inc. ALT | NCT05989711 IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) | Non-Alcoholic Steatohepatitis (NASH) | completed | 212 |
| 2025-11-25 | P3 | Sanofi SNY | NCT06181435 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate- | Dermatitis Atopic | completed | 589 |
| 2025-11-25 | P3 | Bristol-Myers Squibb BMY | NCT06253221 A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Cardiomyopathy, Hypertrophic | active not recruiting | 44 |
| 2025-11-25 | P2 | Boehringer Ingelheim | NCT06335303 A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | completed | 322 |
| 2025-11-25 | P3 | AbbVie ABBV | NCT06387394 A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence | Masseter Muscle Prominence | completed | 202 |
| 2025-11-25 | P3 | Alvotech Swiss AG ALVO | NCT06570772 Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio | Ulcerative Colitis | terminated | 301 |
| 2025-11-25 est. | P2 | Marzieh Ebrahimi | NCT06687681 Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas | Glioma Glioblastoma Multiforme; High Grade Glioma (III or IV) | recruiting | 40 |
| 2025-11-25 | P3 | Vincentage Pharma Co., Ltd | NCT06939296 A Research Study of VCT220 in Adult Chinese Participants With Obesity | Obesity; Overweight | completed | 840 |
| 2025-11-26 | P2 | CUTISS AG | NCT03229564 Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children | Burns | active not recruiting | 12 |
| 2025-11-26 | P1/P2 | RemeGen Co., Ltd. | NCT05508334 A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours | Advanced Solid Tumours | completed | 41 |
| 2025-11-26 | P2 | Keymed Biosciences Co.Ltd | NCT06116565 A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | completed | 263 |
| 2025-11-26 | P2 | Nektar Therapeutics NKTR | NCT06340360 A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) | Alopecia Areata | completed | 94 |
| 2025-11-26 | P2 | Chengdu Zenitar Biomedical Technology Co., Ltd | NCT06457425 A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis | MF,PMF,PPV-MF,PET-MF | active not recruiting | 75 |
| 2025-11-27 | P3 | GB002, Inc. | NCT05934526 Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) | Pulmonary Arterial Hypertension | completed | 390 |
| 2025-11-27 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06091748 Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors | Advanced Gastroenteropancreatic Neuroendocrine Tumor | completed | 69 |
| 2025-11-28 | P2 | Aurealis Oy | NCT06111183 Evaluation of AUP12602-C as New Topical Treatment for DFUs (DIAMEND STUDY) | Diabetic Foot Ulcer | completed | 64 |
| 2025-11-28 | P3 | Angitia Biopharmaceuticals | NCT06115512 A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion | Degenerative Disc Disease | terminated | 412 |
| 2025-11-28 | P2 | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | NCT07132983 A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ens | Chronic Obstructive Pulmonary Disease | completed | 33 |
| 2025-11-29 est. | P3 | RemeGen Co., Ltd. | NCT05727397 Efficacy and Safety of RC28-E Versus Aflibercept | Wet Age-related Macular Degeneration | unknown | 432 |
| 2025-11-30 est. | P3 | Cinnagen | NCT03391934 Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | unknown | 234 |
| 2025-11-30 | P1/P2 | Klus Pharma Inc. | NCT04152499 Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) | Epithelial Ovarian Cancer; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Urothel | active not recruiting | 1410 |
| 2025-11-30 est. | P1/P2 | Binhui Biopharmaceutical Co., Ltd. | NCT04616443 OH2 Injection in Combination With HX008 for Melanoma. | Melanoma | recruiting | 60 |
| 2025-11-30 | P2 | IO Biotech | NCT05077709 IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | Lung Cancer Non Small Cell; Head and Neck Squamous Cell Carcinoma; Urothelial Carcinoma Bladder | completed | 63 |
| 2025-11-30 | P1/P2 | RS Oncology LLC | NCT05278975 Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma | Malignant Pleural Effusion; Malignant Pleural Mesothelioma; Mesothelioma; Mesotheliomas Pleural; Mes | completed | 50 |
| 2025-11-30 est. | P1/P2 | Frontera Therapeutics | NCT05858983 Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy | Biallelic RPE65 Mutation-associated Retinal Dystrophy | recruiting | 9 |
| 2025-11-30 est. | P1/P2 | Biotheus Inc. | NCT05918445 PM8002 in the Treatment of Patients With Advanced Solid Tumors | Malignant Neoplasm | recruiting | 380 |
| 2025-11-30 est. | P1/P2 | SUNHO(China)BioPharmaceutical CO., Ltd. | NCT05991583 A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors | Advanced Malignant Tumors | recruiting | 25 |
| 2025-11-30 est. | P1/P2 | Ascentawits Pharmaceuticals, Ltd | NCT06239155 A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors | Advanced Solid Tumors; Hepatocellular Carcinoma | active not recruiting | 51 |
| 2025-11-30 est. | P3 | Leadiant Biosciences, Inc. | NCT06260748 A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX) | Cerebrotendinous Xanthomatoses | withdrawn | |
| 2025-11-30 est. | P3 | CSPC Ouyi Pharmaceutical Co., Ltd. | NCT06451666 Safety and Efficacy Study of Pilocarpine HCl Ophthalmic Solution in Participants With Presbyopia | Presbyopia | unknown | 330 |
| 2025-11-30 est. | P2 | Evon Medics LLC | NCT06671132 Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P) | Chronic Pain; Low Back Pain | unknown | 220 |
| 2025-11-30 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06689163 A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone | Prostate Cancer | recruiting | 66 |
| 2025-11-30 | P1/P2 | NGGT (Suzhou) Biotechnology Co., Ltd. | NCT06706427 Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy Subjects | Bietti Crystalline Corneoretinal Dystrophy | active not recruiting | 12 |
| 2025-11-30 est. | P3 | Sinovac Biotech Co., Ltd SVA | NCT06734832 Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell) | Hand, Foot, and Mouth Disease(HFMD) | recruiting | 8000 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.